Erlotinib

Form: Oral Tablets

Strength: 25 mg, 100 mg, 150 mg

Reference Brands: Tarceva® (US & EU)

Category: Oncology Cancer Care

Erlotinib Tablets are a targeted oncology treatment used in the EU and US, primarily indicated for non-small cell lung cancer (NSCLC) with EGFR mutations and advanced pancreatic cancer. As a tyrosine kinase inhibitor (TKI), Erlotinib works by inhibiting the epidermal growth factor receptor (EGFR), slowing cancer cell proliferation. Available in 25 mg, 100 mg, and 150 mg strengths, Erlotinib is marketed under the brand name Tarceva® and widely distributed as a generic formulation across global markets. Pharmaceutical distributors and B2B buyers rely on Erlotinib as a high-value, targeted therapy with well-established clinical efficacy in precision oncology.